GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-04-05

Last Posted Date: 2019-02-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 9

Registration Number: NCT02728206

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-03-30

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 119

Registration Number: NCT02722837

Locations: 🇷🇺
Central Research Institute of Epidemiology, Moscow, Russian Federation
🇷🇺
First Moscow State Medical University I.M. Sechenov, Moscow, Russian Federation
🇷🇺
Limited Liability Company "Clinic Tour", Moscow, Russian Federation

and more 12 locations

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Phase 3

Completed

Conditions: HCV Infection
HIV-1 Infection

Interventions: Drug: E/C/F/TAF
Drug: F/R/TAF
Drug: LDV/SOF

First Posted Date: 2016-03-14

Last Posted Date: 2018-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 150

Registration Number: NCT02707601

Locations: 🇺🇸
Be Well Medical Center, Berkley, Michigan, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 39 locations

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Phase 2

Terminated

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: ENTO
Drug: Placebo

First Posted Date: 2016-03-08

Last Posted Date: 2018-12-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT02701634

Locations: 🇫🇷
Hopital Saint Louis, Paris Cedex 10, France
🇪🇸
Hospital Universitario de Salamanca, Salamanca, Spain
🇩🇪
Universitatsklinikum Frankfurt, Frankfurt am Main, Germany

and more 27 locations

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Hu5F9-G4

First Posted Date: 2016-02-09

Last Posted Date: 2019-02-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 20

Registration Number: NCT02678338

Locations: 🇬🇧
St. James University Hospital, Leeds, United Kingdom
🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇬🇧
The Royal Liverpool University Hospital, Liverpool, United Kingdom

and more 2 locations

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-02-02

Last Posted Date: 2019-01-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 375

Registration Number: NCT02671500

Locations: 🇻🇳
Bach Mai Hospital, Hanoi, Vietnam
🇲🇾
Hospital Tengku Ampuan Afzan, Pahang, Malaysia
🇸🇬
National University Hospital, Singapore, Singapore

and more 35 locations

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Cilofexor
Drug: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2020-10-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT02654002

Locations: 🇺🇸
SeaView Research, Inc, Miami, Florida, United States

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: B/F/TAF
Drug: E/C/F/TAF
Drug: E/C/F/TDF
Drug: ATV
Drug: RTV
Drug: FTC/TDF

First Posted Date: 2016-01-12

Last Posted Date: 2020-03-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 472

Registration Number: NCT02652624

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL/VOX
Drug: SOF/VEL

First Posted Date: 2015-12-24

Last Posted Date: 2019-03-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 333

Registration Number: NCT02639247

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL
Drug: SOF/VEL/VOX

First Posted Date: 2015-12-24

Last Posted Date: 2019-03-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 220

Registration Number: NCT02639338

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy